Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tests don't work? I don't know if these are the same kits but is says Spain had to return some quick test kits to China because they did not work.
https://www.foxnews.com/world/china-italy-coronavirus-supplies-buy-back
I haven't seen anything that says Aytu actually submitted the test to the FDA. Did I miss something?
@bluechip I tried the superberry, maybe I just made it too strong. So based on your recommendation I will order some peach.
I tried the berry flavor and wasn't impressed. Has anyone tried the peach flavor?
Don't let the 6% price rise fool you. The sellers outnumbered the buyers by more than a 2:1 margin today.
@WhiskeyBusiness DBE had years to prepare their website and launch plans. Specifically it was DBE's Chris Avery who was in charge of preparing to launch. He failed miserably in this task yet Chaz hires him from DBE and makes him VP of Global Operations. Makes no sense to me.
As far as trading above $1 before January...we all know that isn't going to happen. There is absolutely nothing planned that would cause the SP to rise like that. I predicted .50's in November and I predict .40's before the year is over. Then another 5 or 6 months before UK launch so the SP will continue it's decline well into 2020.
I believe there is something else going on with the product that we are not aware of. Something that caused the FDA to send sugarBeat back to Nemaura's drawing board. It could be a long time before this thing actually launches.
The big lie continues.....
"Nemaura Medical Inc (NASDAQ:NMRD) revealed with second-quarter results on Monday that it was executing aggressively on its commercial strategy for SugarBEAT, the world’s first painless glucose monitor.
Nemaura launched shipments of its SugarBEAT continuous glucose monitors to patients in August in the UK. The wave of shipments is Nemaura’s first foray into the European market after receiving its CE ark, an EU seal of approval, in May."
How can Nemaura launch into Europe when DBE has the rights to Europe? And DBE's website is not excepting orders.
Why are the sales not recorded on the just released 10Q?
Why did they not disclose the number of units sold?
Again, this fake press release is designed to prop up the SP with double talk meant to misinform.
Will SP hit .50's by Friday??
@MarketGeometry The strange thing is there was no selloff. Today was one of those rare days when the buyers outnumbered the sellers 45K to 16K.
Maybe the market makers recognized today's re-release of the fake commercial launch news for what it is.
@Think As stated before I am sitting on less than a 1000 shares as I strategically sold most of my position at 1.05. I saw the downward trend coming. However, I have drunken enough NMRD Kool Aid as to believe this company has a lot of potential and I'm looking for a strategic re-entry point which now looks like late February.
Think, for whatever it's worth, it does not make any sense to ride this stock all the way down. If you believe the SP will continue to go down in the next 8 months before launch you should consider selling and re-buying at a lower price. You will end up with more shares that way.
I would also recommend researching the strategies of using a stop loss. Properly executed you can end up with a lot more shares using the same amount of money. IMHO
@Think4 Be patient, they expressed plans to launch in another 6-8 months, presumably when things are a little less hectic at the polo club and they can focus a little attention on sugarBeat.
Now if these idiots were smart they would assist DBE in putting a professional website together instead of that garbage that's online now. Maybe incorporate some of those "disrupt the industry" videos.
In all seriousness, with the launch coming 6 months after whatever happens on January 11th I can see the SP dipping down into the .30's or even lower. In the last year the stock dropped 65% even with CE approval.
8 more months is a LONG time!
Quote of the day:
" Dr. Faz Chowdhury, CEO of Nemaura commented, “With our current scale of manufacturing in United Kingdom and the first shipments of SugarBEAT® CGM devices to diabetic and pre-diabetic patients, we believe we are well positioned to move aggressively into the commercial phase of our strategy in Europe."
(from the previously cited First Shipments link)
The Big Lie: Remember this press release?
"Nemaura Medical Announces First Shipments of SugarBEAT® Devices to Diabetic and Pre-Diabetic Patients as Part of its First..."
Dr. Faz Chowdhury, CEO of Nemaura Medical, stated, “We are very pleased to have commenced the first phase of our commercial launch. This represents a major achievement for the Company as we transition from product development to a full-fledged commercial organization.”
Everybody on the boards were excited as was the intention of the headline. Yet there were no details of the mysterious shipments.
That was on August 7th. For the 10Q ending September 30, 2019 Nemaura reported 0 revenue. The 10Q makes no mention of any pending accounts receivable, which would be a big deal, right? Their first receivables?
https://ih.advfn.com/stock-market/NASDAQ/nemaura-medical-NMRD/stock-news/80491243/nemaura-medical-announces-first-shipments-of-sugar
Something just doesn't add up. Is there a reasonable explanation for this other than an attempt to manipulate the SP with flagrant false information?
@iddrisw Man, you got that right. I haven't found any evidence of them having distribution experience. And the cheap look of that website won't help them either.
Who last year would have believed that it would take Nemaura almost a year to launch after CE approval? So much for Chaz's aggressive launch!
The SP is .66 in part to unusually heavy selling before today's release of the 10Q. Like triple the volume. There is no way one can look at the level of trading right before a news event and not conclude there is inside trading occurring on a regular basis.
Here we go again, more delays! From todays 10Q:
Note 3: "As the Company now expects commercialization of the sugarBEAT device to occur in the first quarter ending June 30, 2020"
They are going by Nemaura's fiscal year, not calendar year.
So Dallas Burston won't be ready to launch until at least April, 2020. Due to the NASDAQ Rule 5550(a)(2) requiring listed securities to maintain a minimum closing bid price of $1.00 per share by January 11, 2020 and the continued delay by Dallas Burston I can easily see the SP going down into the .30's or worse over the next 4 months.
@Think4 Dallas Burston has the power avert the share value fiasco coming in January. All he has to do is commence commercialization of the android version ASAP and accept online "expressions of interest" for the soon to be released iOS version.
Then watch how fast the SP exceeds $1.
@finesand One of the things that keep nagging at the back of my brain is the disclosure that their privately owned Nemaura Pharma will receive residuals from the sales of publicly owned Nemaura Medical in I believe it was in a recent quarterly report. It did not state the amount of the residual.
I can see a few scenarios of how this could end up screwing the SH.
@finesand Reverse ionotophoresis has been proven. First with the GlucoWatch, which eventually failed because the battery was laying on the skin and causing burns, as opposed to sugarBeat which draws fluid into a cup shaped chamber. Reverse iontophoresis was further proven via CE approval two times for sugarBeat.
The only thing unproven is Dallas Burston's ability to market this product before what's left of shareholders value is destroyed on January 11th.
For some reason there is a healthy increase in institutional positions in DF.
https://mitchellmessenger.com/2019/10/29/invesco-ltd-raises-position-in-dean-foods-co-nysedf-updated.html
@WhiskeyBusiness Operational in what way?
Almost 90% of the 84 trades this morning were sell orders, not exactly something to get all excited about.
What I did find interesting is how the SP price rose 2.7% despite overwhelming selling.
Just had a thought. The people in the UK that see this and similar articles about sugarBeat...do they have a way of knowing that it will be sold in Europe as MySugarWatch?? Is there a conspicuous link on Nemaura's website that redirects consumers to DBE?
I wonder how much revenue is going to be lost because of the stupid private label agreement?
Lets see... 81.3 million monthly US visitors to that website. 9.4% are diabetic. So aprox 7.6 million diabetics may have seen the article. Maybe higher as it's a health orientated website. That's a lot of exposure!
This is actually the single best piece of news I've seen since I started investing in this stock a year and a half ago. Too bad it's a mostly wasted opportunity due to the delays.
@ Dia bet Another great find, this article contains a lot of new info. Here's my take on a a few things I found interesting:
1) "Meanwhile, Nemaura is predicting that its system may cost less than one-fifth of competing products:
$30 per month annual subscription plan for non-insulin users -- includes 8 patches/month, transmitter and recharger
$55 per month annual subscription for insulin users -- includes 16 patches/month, transmitter and recharger"
Finally,prices! Is 16 patches enough for insulin users?? Not for me. I hope the subscription is more flexible regarding quantity.
2) "However, EASD study did not publish the accuracy data associated with the important low blood sugar zone of <80 mg/dL. In this January 2018 presentation, SugarBEAT’s MARD was 19.28% in the 61-80 mg/dL range, and 26.92% in the 40-60 mg/dL range."
"They do expect accuracy to improve as the product matures."
This might possibly be a barrier to FDA approval as low sugar levels are much more dangerous then high levels. At the US Dept of Veteran Affairs GCMs are approved based solely on low sugar levels.
@Think4 Along that line I find it interesting why Dr. Fred is doing all the talking when DBE's flunky Chris Avery outranks him. Avery is Vice President of Global Business Operations at Nemaura. Dr. Fred is Vice President of Strategy & Strategic Alliances.
Because Avery was working in Dallas Burstons interest I have no idea why DBE dumped him unto Nemaura's payroll. Burston obviously wanted to get rid of him. On his LinkedIn profile Avery takes credit for developing MySugarWatch's website, a website which he failed to create before he left.
@iddrisw I concur with your prediction. If only that idiot Dallas Burston would step up and launch by mid December some of this could be avoided.
With privately owned Nemaura Pharma having 16 items in the pipeline and Dallas Burston focused on a $100 million renovation of his namesake business, none of the principals involved will ever devote more than a part time attention to this product.
I'm guessing that Nemaura has already received some negative feedback from FDA, which is why they are now projecting approval & US launch by the end of next year.
@Whiskey The series of videos from the conference?
Bottom line: All the time last year when Chaz was telling us he was ready to launch within 30 days of CE approval he was lying. He was intentionally lying to us to prop up the SP. Here it is 5 months after CE approval and DBE is still working on the trademark with another estimated 3 months before they launch.
There is no way Chaz did NOT know DBE was nowhere close to being able to launch. Also, remember that Burston will never give this product anything more than his part time attention due to his other businesses. This is not an optimum situation.
It could be worse. He was toying with the idea of calling sugarBeat Binky Watch, and even registered the names. That being said, Sugar.Watch is really amateurish, and the dot could interfere with web searches.
PawPaw That looks like THE ios app for sugarbeat, sugarwatch, sugar.watch or whatever the name is this week. It says its for the SugarWatch. Nice catch!
Marketing update: The DBE geniuses changed the private label name from MySugarWatch to Sugar.Watch. Doesn't that dot roll off the tongue? Ok, maybe not. Looks like a few other minor changes to the site too.
@Think I hope it goes even lower. This is not a long play until at least mid December. Make some money now so you can accumulate more shares later. Right now the money is easy on this stock...the trend is so predictable. Especially with this commission free trading.
@Whiskey Thank you for the post. So the launch is scheduled for January but he mumbled something after saying they expected FDA approval soon. Something about contacting the manufacturer. Did he say he was expecting FDA in January as well?
Looks like this might be the week this stock falls into the 60's. I don't see any positive news coming from either launch or FDA approval before the beginning of next year. I'm thinking March is more realistic. I could easily see 50's before this month is over, November should be really ugly.
However, with no-commission trading and really low SP's it might be a good idea to pick up however few or many shares you can over the next few months. GLTA
At 74 cents I'll add a couple thousand shares today but I think it will go lower.
News headline: "Nemaura Medical Provides Update Regarding Commercial Launch of SugarBEAT"
Did anyone see any update of the commercial launch in the videos? Or is this a fake headline?
@Think Read the posts today. The product is not available yet...a minor detail Faz forgot to mention.
@iddrisw I think you are totally correct about the delay being caused by the lack of ios. Chaz says in the video (if you can believe him anymore) that ios should be ready in the next 2 weeks and is undergoing verification now. After that is all the logistics that then go into arranging for the manufacture of ios which would push it into next year, DBE's time frame.
When you consider the European launch is going to be centered on the MySugarWatch website it makes perfect sense to delay until ios is ready. Great observation!
@iddrsw What I found interesting is when Chaz stated that they CURRENTLY have the production capacity in the UK to meet the anticipated demands of 4-5 major European territories, including the UK.
What this tells me is that the current delay is not due to the inability to produce product, but the inability or unwillingness of Dallas Burston to execute his end of the partnership in a timely manner. Also, if you think about it, DB will give any more then part time attention to MySugarWatch due to his other business interests.
This product deserves better than that.